首页> 外文期刊>Nephrology Dialysis Transplantation >No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy—report from the ItalKid Project database
【24h】

No clear evidence of ACEi efficacy on the progression of chronic kidney disease in children with hypodysplastic nephropathy—report from the ItalKid Project database

机译:ACEi对发育不良性肾病患儿慢性肾脏病进展的疗效尚无明确证据-来自ItalKid Project数据库的报告

获取原文
获取原文并翻译 | 示例
           

摘要

Background. Chronic kidney diseases (CKD) tend to progress to end-stage renal failure (ESRF). As it has been demonstrated that angiotensin-converting enzyme inhibitors (ACEi) have a renoprotective effect in adults with proteinuric disease and may be effective in reducing hyperfiltration and proteinuria, they are also frequently used as anti-progression agents in paediatric patients with CKD despite the lack of data confirming their role in the nephropathies peculiar to children. The aim of this study was to investigate whether patients with hypodysplastic CKD (the most common cause of ESRF in children) treated with ACEi show a significantly slower decline in creatinine clearance (Ccr).
机译:背景。慢性肾脏疾病(CKD)倾向于发展为终末期肾衰竭(ESRF)。由于已经证明血管紧张素转化酶抑制剂(ACEi)在患有蛋白尿症的成人中具有肾脏保护作用,并且可能有效减少超滤和蛋白尿,尽管它们在儿童中也常被用作抗进展药物。缺乏数据证实其在儿童特有的肾病中的作用。这项研究的目的是调查接受ACEi治疗的发育不良性CKD(儿童ESRF的最常见原因)患者的肌酐清除率(Ccr)下降是否明显减慢。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号